Terence Flynn
Stock Analyst at Morgan Stanley
(2.81)
# 1,719
Out of 4,873 analysts
192
Total ratings
58.82%
Success rate
2.23%
Average return
Main Sectors:
Stocks Rated by Terence Flynn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARVN Arvinas | Maintains: Equal-Weight | $12 → $11 | $7.75 | +41.94% | 9 | May 9, 2025 | |
| RCUS Arcus Biosciences | Maintains: Overweight | $24 → $22 | $8.63 | +154.92% | 6 | May 9, 2025 | |
| BNTX BioNTech SE | Maintains: Overweight | $140 → $132 | $103.50 | +27.54% | 3 | May 6, 2025 | |
| OGN Organon & Co. | Maintains: Equal-Weight | $15 → $10 | $9.96 | +0.45% | 10 | May 5, 2025 | |
| UTHR United Therapeutics | Maintains: Equal-Weight | $346 → $348 | $285.75 | +21.78% | 9 | May 1, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $241 → $250 | $186.00 | +34.41% | 16 | Apr 28, 2025 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $164 → $169 | $152.65 | +10.71% | 21 | Apr 16, 2025 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,146 → $1,124 | $793.14 | +41.72% | 19 | Apr 9, 2025 | |
| AMGN Amgen | Maintains: Equal-Weight | $328 → $330 | $277.29 | +19.01% | 8 | Apr 9, 2025 | |
| BHVN Biohaven | Maintains: Overweight | $69 → $63 | $14.20 | +343.66% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $30 → $32 | $47.36 | -32.43% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $113 → $106 | $79.31 | +33.65% | 16 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $17 | $11.41 | +48.99% | 4 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $56 → $11 | $9.41 | +16.96% | 5 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $36 → $39 | $46.53 | -16.18% | 10 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $31 | $24.25 | +27.84% | 17 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $118 | $22.03 | +435.63% | 1 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $36 | $2.93 | +1,128.67% | 1 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $51 | $35.81 | +42.42% | 11 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $121 → $168 | $128.30 | +30.94% | 6 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1 → $8 | $1.50 | +435.12% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $246 → $436 | $126.29 | +245.24% | 3 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $322.87 | - | 2 | Oct 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.60 | - | 1 | Jul 21, 2017 |
Arvinas
May 9, 2025
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $7.75
Upside: +41.94%
Arcus Biosciences
May 9, 2025
Maintains: Overweight
Price Target: $24 → $22
Current: $8.63
Upside: +154.92%
BioNTech SE
May 6, 2025
Maintains: Overweight
Price Target: $140 → $132
Current: $103.50
Upside: +27.54%
Organon & Co.
May 5, 2025
Maintains: Equal-Weight
Price Target: $15 → $10
Current: $9.96
Upside: +0.45%
United Therapeutics
May 1, 2025
Maintains: Equal-Weight
Price Target: $346 → $348
Current: $285.75
Upside: +21.78%
AbbVie
Apr 28, 2025
Maintains: Overweight
Price Target: $241 → $250
Current: $186.00
Upside: +34.41%
Johnson & Johnson
Apr 16, 2025
Maintains: Equal-Weight
Price Target: $164 → $169
Current: $152.65
Upside: +10.71%
Eli Lilly and Company
Apr 9, 2025
Maintains: Overweight
Price Target: $1,146 → $1,124
Current: $793.14
Upside: +41.72%
Amgen
Apr 9, 2025
Maintains: Equal-Weight
Price Target: $328 → $330
Current: $277.29
Upside: +19.01%
Biohaven
Mar 7, 2025
Maintains: Overweight
Price Target: $69 → $63
Current: $14.20
Upside: +343.66%
Feb 14, 2025
Maintains: Underweight
Price Target: $30 → $32
Current: $47.36
Upside: -32.43%
Feb 5, 2025
Maintains: Equal-Weight
Price Target: $113 → $106
Current: $79.31
Upside: +33.65%
Feb 3, 2025
Maintains: Equal-Weight
Price Target: $16 → $17
Current: $11.41
Upside: +48.99%
Jan 27, 2025
Downgrades: Equal-Weight
Price Target: $56 → $11
Current: $9.41
Upside: +16.96%
Nov 12, 2024
Maintains: Underweight
Price Target: $36 → $39
Current: $46.53
Upside: -16.18%
Oct 30, 2024
Maintains: Equal-Weight
Price Target: $30 → $31
Current: $24.25
Upside: +27.84%
Sep 23, 2024
Initiates: Overweight
Price Target: $118
Current: $22.03
Upside: +435.63%
Jul 23, 2024
Initiates: Overweight
Price Target: $36
Current: $2.93
Upside: +1,128.67%
Jul 11, 2024
Maintains: Overweight
Price Target: $48 → $51
Current: $35.81
Upside: +42.42%
May 6, 2024
Maintains: Buy
Price Target: $121 → $168
Current: $128.30
Upside: +30.94%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $1 → $8
Current: $1.50
Upside: +435.12%
Jun 14, 2021
Maintains: Neutral
Price Target: $246 → $436
Current: $126.29
Upside: +245.24%
Oct 2, 2017
Upgrades: Buy
Price Target: n/a
Current: $322.87
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $5.60
Upside: -